Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| In Vitro Fertilization … | Healthcare Services | 38.2% | 94th pct | 268 |
| Beta Plus Pertiliti | Healthcare Services | 32.0% | 91st pct | 268 |
| Timi - Tbilisis Meditsi… | Healthcare Services | 10.5% | 51st pct | 268 |
| Acad. V. Iverieli Cente… | Healthcare Services | 9.6% | 49th pct | 268 |
| Kartul-Germanuli Reprod… | Healthcare Services | 9.4% | 49th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | In Vitro Fertilization … | Kartul-Germanuli Reprod… | Beta Plus Pertiliti | Timi - Tbilisis Meditsi… | Acad. V. Iverieli Cente… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 82.8% | 51.4% | 89.0% | 72.8% | 38.0% |
| EBITDA Margin | 38.2% | 9.4% | 32.0% | 10.5% | 9.6% |
| EBITDAR | 9,734 | 2,117 | 5,383 | 2,201 | 1,266 |
| EBITDAR Margin | 38.2% | 9.4% | 36.0% | 15.4% | 9.7% |
| EBIT Margin | 34.9% | 4.0% | 30.3% | 7.2% | 7.8% |
| Net Profit Margin | 36.7% | 2.0% | 32.0% | 7.3% | 8.3% |
| Operating Expense % of Sales | 44.7% | 42.0% | 57.0% | 62.3% | 28.4% |
| Returns | |||||
| Return on Assets (ROA) | 29.4% | 2.3% | 31.8% | 13.8% | 5.9% |
| Return on Equity (ROE) | 33.4% | 7.7% | 32.4% | 33.2% | 9.0% |
| ROIC [EBIT / Invested Capital] | 48.7% | ||||
| 5.5% |
| 68.3% |
| 25.2% |
| 8.4% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 4.8% | 58.1% | 1.0% | 14.4% | 1.8% |
| Debt-to-Equity | 0.05x | 1.93x | 0.01x | 0.35x | 0.03x |
| Debt-to-EBITDA | 0.16x | 5.40x | 0.03x | 0.73x | 0.27x |
| Equity-to-Assets | 88.1% | 30.1% | 98.1% | 41.4% | 64.8% |
| Net Debt | -9,701 | 10,523 | -8,137 | 962 | 99 |
| Cash & Equivalents | 11,237 | 916 | 8,282 | 128 | 240 |
| Total Debt | 1,536 | 11,440 | 145 | 1,090 | 339 |
| Liquidity & working capital | |||||
| Current Ratio | 5.70x | 1.99x | 29.23x | 1.31x | 1.20x |
| Quick Ratio | 5.42x | 1.99x | 29.23x | 1.31x | 0.94x |
| Cash Ratio | 4.64x | 0.39x | 29.23x | 0.04x | 0.04x |
| Total Current Assets | 13,795 | 4,655 | 8,282 | 4,397 | 7,447 |
| Total Current Liabilities | 2,420 | 2,338 | 283 | 3,346 | 6,184 |
| Inventory | 690 | N/A | N/A | N/A | 1,617 |
| Trade Receivables | 1,709 | 2,670 | 3,507 | 2,263 | 944 |
| Trade Payables | 1,469 | 1,598 | 17 | 3,346 | 6,184 |
| Net Working Capital | 11,375 | 2,317 | 7,998 | 1,051 | 1,263 |
| Net Working Capital % of Revenue | 44.6% | 10.3% | 53.4% | 7.4% | 9.7% |
| Trade Working Capital | 930 | 1,071 | 3,490 | -1,083 | -3,624 |
| Trade Working Capital % of Revenue | 3.6% | 4.7% | 23.3% | -7.6% | -27.8% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 6.34x | N/A | N/A | N/A | 5.00x |
| Days Inventory Outstanding (DIO) | 57.6 | N/A | N/A | N/A | 72.9 |
| Receivables Turnover | 14.91x | 8.46x | 4.27x | 6.30x | 13.83x |
| Days Sales Outstanding (DSO) | 24.5 | 43.1 | 85.5 | 57.9 | 26.4 |
| Payables Turnover | 2.98x | 6.87x | 96.49x | 1.16x | 1.31x |
| Days Payable Outstanding (DPO) | 122.6 | 53.1 | 3.8 | 314.9 | 278.9 |
| Cash Conversion Cycle | -40.5 days | -10.0 days | 81.7 days | -256.9 days | -179.6 days |
| Asset Turnover | 0.80x | 1.15x | 0.99x | 1.88x | 0.70x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 10,370 | 1,317 | 5,519 | 406 | 2,788 |
| Free Cash Flow (OCF − Capex proxy) | 9,864 | -1,321 | 5,519 | -280 | -215 |
| Cash Conversion (OCF / EBITDA) | 106.5% | 62.2% | 115.0% | 27.1% | 223.3% |
| Dividends Declared | 0 | N/A | N/A | N/A | 176 |
| Dividend Payout Ratio | 0.0% | N/A | N/A | N/A | 16.2% |